Chemical validation of phosphodiesterase C as a chemotherapeutic target in Trypanosoma cruzi, the etiological agent of Chagas' disease.

Antimicrobial Agents and Chemotherapy
Sharon King-KellerRoberto Docampo

Abstract

Trypanosoma cruzi phosphodiesterase (PDE) C (TcrPDEC), a novel and rather unusual PDE in which, unlike all other class I PDEs, the catalytic domain is localized in the middle of the polypeptide chain, is able to hydrolyze cyclic GMP (cGMP), although it prefers cyclic AMP (cAMP), and has a FYVE-type domain in its N-terminal region (S. Kunz et al., FEBS J. 272:6412-6422, 2005). TcrPDEC shows homology to the mammalian PDE4 family members. PDE4 inhibitors are currently under development for the treatment of inflammatory diseases, such as asthma, chronic pulmonary diseases, and psoriasis, and for treating depression and serving as cognitive enhancers. We therefore tested a number of compounds originally synthesized as potential PDE4 inhibitors on T. cruzi amastigote growth, and we obtained several useful hits. We then conducted homology modeling of T. cruzi PDEC and identified other compounds as potential inhibitors through virtual screening. Testing of these compounds against amastigote growth and recombinant TcrPDEC activity resulted in several potent inhibitors. The most-potent inhibitors were found to increase the cellular concentration of cAMP. Preincubation of cells in the presence of one of these compounds stimulated volume r...Continue Reading

References

Dec 30, 1971·Annals of the New York Academy of Sciences·W J Thompson, M M Appleman
Jun 1, 1993·Molecular and Biochemical Parasitology·R DocampoA E Vercesi
May 15, 1998·The New England Journal of Medicine·I GoldsteinP A Wicker
Dec 29, 2000·Journal of Computer-aided Molecular Design·G M VerkhivkerP W Rose
Apr 12, 2001·Journal of Medicinal Chemistry·M Stahl, M Rarey
Jun 8, 2001·Journal of Computer-aided Molecular Design·T J EwingI D Kuntz
Oct 24, 2002·Journal of Computational Chemistry·Araz JakalianChristopher I Bayly
Feb 13, 2003·Biopolymers·Mark R McGannFrank K Brown
Mar 5, 2003·Molecular and Biochemical Parasitology·Peter RohloffR Docampo
Mar 21, 2003·Medicinal Research Reviews·Ingo Muegge
Oct 29, 2003·Trends in Parasitology·Julio A Urbina, Roberto Docampo
Sep 11, 2004·Current Molecular Medicine·T SeebeckA Johner
Oct 7, 2004·The Journal of Biological Chemistry·Peter RohloffRoberto Docampo
Dec 4, 2004·Structure·Graeme L CardKam Y J Zhang
Apr 29, 2005·Journal of Medicinal Chemistry·Yan LingEric Oldfield
Oct 4, 2005·Journal of Computational Chemistry·David A CaseRobert J Woods
Oct 18, 2005·Molecular and Biochemical Parasitology·Guillermo D AlonsoMirtha M Flawiá
Dec 13, 2005·The FEBS Journal·Stefan KunzThomas Seebeck
Mar 3, 2006·Current Opinion in Structural Biology·Krzysztof Ginalski
Apr 26, 2006·Drug Discovery Today·Miklos Feher
Jul 4, 2006·Molecular and Biochemical Parasitology·Huan HuangYi Bao
Dec 7, 2006·Journal of Computer-aided Molecular Design·Demetri T MoustakasRobert C Rizzo
Sep 11, 2007·Molecular Interventions·Sunil Laxman, Joseph A Beavo
Feb 12, 2008·Biochemical and Biophysical Research Communications·Minyong LiBinghe Wang
May 27, 2008·Bioorganic & Medicinal Chemistry Letters·Keng-Chang TsaiBinghe Wang
Jul 16, 2008·Journal of Molecular Modeling·Minyong LiBinghe Wang

❮ Previous
Next ❯

Citations

Jun 3, 2000·Parasitology Research·K MirandaW de Souza
Aug 24, 2011·Future Medicinal Chemistry·Michael P Pollastri, Robert K Campbell
Jun 1, 2012·Expert Opinion on Drug Discovery·Juan M BustamanteUNKNOWN The Chagas Drug Discovery Consortium
Jul 15, 2011·Cell Calcium·Roberto Docampo, Silvia N J Moreno
Nov 3, 2015·Molecular and Biochemical Parasitology·Roberto Docampo
May 26, 2015·Trends in Parasitology·Laura Makin, Eva Gluenz
Jan 13, 2011·FEMS Microbiology Reviews·Matthew K Gould, Harry P de Koning
Aug 15, 2018·Antimicrobial Agents and Chemotherapy·Victor Sebastián-PérezCarmen Gil
Dec 21, 2019·The Journal of Antimicrobial Chemotherapy·Julianna Siciliano De AraújoMaria de Nazaré Correia Soeiro
Feb 13, 2020·Parasitology·Claudio A PereiraEdward Valera-Vera
Jun 21, 2019·Current Medicinal Chemistry·Alejandra Cecilia SchoijetGuillermo Daniel Alonso
Feb 11, 2016·Biochemical Society Transactions·Noelia LanderRoberto Docampo
Jun 12, 2019·International Journal of Molecular Sciences·Anacleto S de SouzaAdriano D Andricopulo
Oct 10, 2020·Molecular Microbiology·Noelia LanderRoberto Docampo

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.